Acrivon Therapeutics (ACRV) leaders disclose tax-withholding share dispositions

Rhea-AI Filing Summary

Acrivon Therapeutics insiders reported tax-related share dispositions tied to restricted stock unit vesting. The filing shows 1,302 shares of Common Stock disposed at $1.63 per share, leaving 2,094,469 shares owned following this transaction.

A separate indirect transaction reports a tax-withholding disposition of 579 Common Stock shares at $1.63 per share, with 314,127 shares owned indirectly afterward. Footnotes explain shares were withheld by the issuer to satisfy mandatory tax withholding and that certain holdings are through a spouse, with each spouse disclaiming beneficial ownership beyond their pecuniary interest.

Insights

Equity compensation and governance analyst

Routine tax withholding on RSU vesting with no open-market selling.

The transactions involve Form 4 disclosures by senior leaders of Acrivon Therapeutics, including the President and CEO and the EVP of Business Operations. Both reported Code F dispositions, which indicate shares used to cover tax liabilities on equity awards.

One transaction shows 1,302 Common Stock shares disposed at $1.63 per share, with 2,094,469 shares remaining. Another indirect transaction covers 579 shares at the same price, leaving 314,127 shares indirectly held. Footnotes clarify the issuer withheld shares for mandatory taxes and that spouses hold some securities with each party disclaiming beneficial ownership beyond their pecuniary interest.

These mechanics are typical for equity compensation and do not represent discretionary buying or selling in the market. They mainly reflect tax and ownership-structure reporting, rather than a change in the company’s outlook.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blume-Jensen Peter

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/14/2026		F(1)		1,302	D	$1.63	2,094,469	D(2)
Common Stock	02/14/2026		F(1)		579	D	$1.63	314,127	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Blume-Jensen Peter

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

1. Name and Address of Reporting Person^*

Masson Kristina

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP - Business Operations

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

2. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson?s spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

3. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen?s spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

	/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen	02/18/2026
	/s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ACRV executives report in this Form 4?

Executives reported tax-withholding dispositions of Acrivon Therapeutics Common Stock. One transaction involved 1,302 shares, another indirectly 579 shares, both at $1.63 per share, related to restricted stock unit vesting rather than open-market trading.

Did ACRV insiders buy or sell shares on the open market?

No open-market buying or selling is shown. The Form 4 reports Code F transactions, where shares were withheld by the issuer to cover tax liabilities upon vesting of restricted stock units, a common equity compensation practice.

How many ACRV shares did insiders dispose of for tax withholding?

Insiders reported disposing of 1,302 Common Stock shares directly and 579 shares indirectly, each at $1.63 per share. These amounts were used solely to satisfy mandatory tax withholding tied to restricted stock unit vesting.

What are the post-transaction share holdings reported for ACRV insiders?

After the tax-withholding dispositions, one insider directly holds 2,094,469 Common Stock shares. An indirect holding account associated with an insider reports 314,127 shares owned after its transaction, reflecting continuing, substantial positions in the company.

How do the ACRV Form 4 footnotes affect ownership interpretation?

Footnotes state shares were withheld by the issuer for mandatory taxes on RSU vesting and that some securities are held by a spouse. Each spouse disclaims beneficial ownership beyond their pecuniary interest, clarifying economic versus formal ownership.

Are the reported ACRV insider transactions considered routine?

Yes, they appear routine. The dispositions are Code F tax-withholding events linked to restricted stock unit vesting. Such transactions commonly occur under equity compensation programs and do not, by themselves, signal a change in insider sentiment.